The size of the Autoimmune Monoclonal Antibodies Market in the Asia Pacific is expected to reach USD 1813.85 million by 2024 from USD 2536.89 million in 2019, growing at a CAGR of 6.94% during the forecast period 2019 - 2024.
Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This leads to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and other diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs have made switched to concentrate on monoclonal antibodies.
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat a wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.
Rising healthcare expenditure, increasing disease patient population associated with lifestyle changes, the growing involvement of universities & research institutes, rising demand for advanced healthcare therapeutics, and the presence of huge population are driving the growth of autoimmune monoclonal antibodies market in Asia-Pacific. However, low adoption of advanced therapies, high cost of monoclonal antibodies therapeutics, and lack of superior research facilities in certain Asian countries are restraining the growth of the autoimmune monoclonal antibodies market in Asia-Pacific.
This research report is segmented & sub-segmented into the following categories:
Prominent companies leading the APAC Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Application
5.2.1 Systemic Lupus Erythematosus
5.2.2 Rheumatoid Arthritis
5.2.3 Multiple Sclerosis
5.2.4 Transplant Rejection/Graft Versus Host Disease
5.2.5 Others
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
6. Geographical Analysis
6.1 Asia-Pacific
6.1.1 Introduction
6.1.2 China
6.1.3 India
6.1.4 Japan
6.1.5 South Korea
6.1.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 AstraZeneca plc (U.K.)
9.6 Innovent Biologics, Inc. (China)
9.4 Bristol-Myers Squibb (U.S.)
9.5 Johnson & Johnson (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.7 Takeda Pharmaceutical Company Ltd. (Japan)
9.8 Amgen Inc. (U.S.)
9.9 Biogen Inc.(U.S.)
9.10 UCB Company (Belgium)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
